QC
HOWL icon

Quadrature Capital’s Werewolf Therapeutics HOWL Stock Holding History

Quadrature Capital’s Portfolio HOWL Stock Details HOWL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-25,791
Closed -$28K – 1234
2025
Q2 		$28K Buy
+25,791
New +$26.5K ﹤0.01% 985

Other funds holding HOWL

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $1.49M AUM 18.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Quadrature Capital's HOWL Position: Q3 2025 in Review

Quadrature Capital sold out of Werewolf Therapeutics (HOWL) in Q3 2025, closing a stake of 25,791 shares — an estimated $28K sold.

Quadrature Capital first reported a position in HOWL in Q2 2025 and held it in 1 quarter. The position peaked at $28K in Q2 2025. 62 funds tracked by Wall St. Rank hold HOWL as of Q3 2025.

  • Quadrature Capital reported no remaining Werewolf Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Quadrature Capital sold 25,791 Werewolf Therapeutics shares in Q3 2025, an estimated $28K.
  • Quadrature Capital first reported a position in Werewolf Therapeutics in Q2 2025 and held it in 1 quarter.
  • Quadrature Capital's Werewolf Therapeutics position peaked at $28K in Q2 2025.
  • 62 funds tracked by Wall St. Rank held Werewolf Therapeutics as of Q3 2025.

Based on Quadrature Capital's 13F filing for Q3 2025, filed 13 Nov 2025.